An Open Label, Multi-center Imatinib Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Imatinib Study and Are Judged by the Investigator to Benefit From Continued Imatinib Treatment
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 25 May 2017
At a glance
- Drugs Imatinib (Primary)
- Indications Chronic myeloid leukaemia; Gastrointestinal stromal tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 09 Sep 2016 Planned End Date changed from 1 Oct 2024 to 1 Jun 2024.
- 09 Sep 2016 Planned primary completion date changed from 1 Oct 2024 to 1 Jun 2024.
- 07 Apr 2016 Planned End Date changed from 1 Sep 2023 to 1 Oct 2024 as reported by ClinicalTrials.gov record.